| Ytd | -75.45% | |
| 1y | -86.99% |
| Open | 0.47 | Prev Close | 0.45 | Low | 0.46 | High | 0.53 | Mkt Cap | 6.92M |
| Vol | 436.33K | Avg Vol | 1.73M | EPS | -2.14 | P/E | N/A | Forward P/E | -9.31 |
| Beta | 7.68 | Short Ratio | 0.66 | Inst. Own | 13.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.66 | 200-d Avg | 1.73 | 1yr Est | 6.30 |
VVOS News
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
Key Terms of the Proposed Rights OfferingExercise price: Each right is expected to entitle the holde
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading me
Top Wall Street analysts updated ratings on CRWD, OLLI, XPO, SHAK, UNH, PVH, VVOS, and SYRE. See ana
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and r
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.52) per share which missed the ana
Wall Street analysts changed their outlook on top names. For all rating changes, see analyst ratings
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and l
HC Wainwright & Co. analyst Yi Chen maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.58) per share which missed the ana
Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transce
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor st
Vivos Therapeutics shares surge 21.21% after hours as a Michigan-based investor group acquires a 19.
Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness marketL
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and l
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.49) per share which missed the ana
HC Wainwright & Co. analyst Yi Chen initiates coverage on Vivos Therapeutics (NASDAQ:VVOS) wi
Previously Unpublished Data Confirms Vivos DNA Devices Offer a Safe and Effective Alternative Treatm
Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading me
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and r
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.55) per share which missed the ana
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in propr
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.45) per share which missed the ana
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and l